Cannabinoid receptors couple to NMDA receptors to reduce the production of NO and the mobilization of zinc induced by glutamate

Antioxidants and Redox Signaling

Volumn 19, Issue 15, 2013, Pages 1766-1782

  Sánchez Blázquez, Pilar ^a   Rodríguez Muñoz, María ^a   Vicente Sánchez, Ana ^a   Garzón, Javier ^a  

^a INSTITUTO CAJAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR; CYCLIC AMP DEPENDENT PROTEIN KINASE; GLUTAMIC ACID; HISTIDINE; HISTIDINE TRIAD NUCLEOTIDE BINDING PROTEIN 1; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NITRIC OXIDE; NUCLEOTIDE BINDING PROTEIN; UNCLASSIFIED DRUG; ZINC ION;

ANALGESIA; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL SURFACE; CONTROLLED STUDY; ENZYME INHIBITION; IMMUNOPRECIPITATION; MOUSE; NERVOUS SYSTEM; NEUROPATHY; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE TYPE 2; CANNABINOIDS; CYCLIC AMP-DEPENDENT PROTEIN KINASES; GLUTAMIC ACID; MICE; MICE, KNOCKOUT; NERVE TISSUE PROTEINS; NERVOUS SYSTEM; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE I; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN KINASE C; RECEPTOR, CANNABINOID, CB1; RECEPTORS, CANNABINOID; RECEPTORS, N-METHYL-D-ASPARTATE; SIGNAL TRANSDUCTION; ZINC;

EID: 84883819557     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2012.5100     Document Type: Article

References (71)

1. Aizenman E, Stout AK, Hartnett K.A., Dineley KE, McLaughlin B, and Reynolds IJ. Induction of neuronal ap-optosis by thiol oxidation: putative role of intracellular zinc release. J Neurochem 75: 1878-1888, 2000.
2. Ajit SK, Ramineni S, Edris W., Hunt RA, Hum WT, Hepler JR, and Young KH. RGSZ1 interacts with protein kinase C interacting protein PKCI-1 and modulates mu opioid receptor signaling. Cell Signal 19: 723-730, 2007. (Pubitemid 46275365)
3. Albensi BC. The NMDA receptor/ion channel complex: a drug target for modulating synaptic plasticity and ex-citotoxicity. Curr Pharm Des 13: 3185-3194, 2007. (Pubitemid 350201695)
4. Antonelli T, Tomasini MC, Tattoli M, Cassano T., Tanganelli S, Finetti S, Mazzoni E., Trabace L, Steardo L, Cuomo V., and Ferraro L. Prenatal exposure to the CB1 receptor agonist WIN 55,212-2 causes learning disruption associated with impaired cortical NMDA receptor function and emotional reactivity changes in rat offspring. Cereb Cortex 15: 2013-2020, 2005. (Pubitemid 41628339)
5. Ashton JC and Milligan ED. Cannabinoids for the treatment of neuropathic pain: clinical evidence. Curr Opin Investig Drugs 9: 65-75, 2008.
6. Bird GC, Lash LL, Han J.S., Zou X., Willis WD, and Neugebauer V. Protein kinase A-dependent enhanced NMDA receptor function in pain-related synaptic plasticity in rat amygdala neurones. J Physiol 564: 907-921, 2005. (Pubitemid 40704153)
7. Brown TM, Brotchie JM, and Fitzjohn SM. Cannabinoids decrease corticostriatal synaptic transmission via an effect on glutamate uptake. J Neurosci 23: 11073-11077, 2003. (Pubitemid 37548941)
8. Cannon M and Clarke MC. Risk for schizophrenia - broadening the concepts, pushing back the boundaries. Schizophr Res 79: 5-13, 2005. (Pubitemid 41362589)
9. Chakravarthy B, Morley P, and Whitfield J. Ca2+-calmod-ulin and protein kinase Cs: a hypothetical synthesis of their conflicting convergences on shared substrate domains. Trends Neurosci 22: 12-16, 1999. (Pubitemid 29130078)
10. Chen L and Huang LY. Sustained potentiation of NMDA receptor-mediated glutamate responses through activation of protein kinase C by alopioid. Neuron 7: 319-326, 1991.
11. Chen Q, Wang X, O'Neill FA, Walsh D, Kendler K.S., and Chen X. Is the histidine triad nucleotide-binding protein 1 (HINT1) gene a candidate for schizophrenia? Schizophr Res 106: 200-207, 2008.
12. Degenhardt L, Hall W, and Lynskey M. Testing hypotheses about the relationship between cannabis use and psychosis. Drug Alcohol Depend 71: 37-48, 2003. (Pubitemid 36734857)
13. Derkinderen P, Valjent E, Toutant M., Corvol JC, Enslen H, Ledent C, Trzaskos J., Caboche J, and Girault JA. Regulation of extracellular signal-regulated kinase by cannabinoids in hippocampus. J Neurosci 23: 2371-2382, 2003. (Pubitemid 36368926)
14. Fan N, Yang H, Zhang J., and Chen C. Reduced expression of glutamate receptors and phosphorylation of CREB are responsible for in vivo Delta9-THC exposure-impaired hippo-campal synaptic plasticity. J Neurochem 112: 691-702, 2010.
15. Fernandez-Espejo E., Viveros MP, Nunez L, Ellenbroek B.A., and Rodriguez de FF. Role of cannabis and en-docannabinoids in the genesis of schizophrenia. Psycho-pharmacology (Berl) 206: 531-549, 2009.
16. Fiorentini C, Gardoni F, Spano P., Di LM, and Missale C. Regulation of dopamine D1 receptor trafficking and desen-sitization by oligomerization with glutamate N-methyl-D-aspartate receptors. J Biol Chem 278: 20196-20202, 2003. (Pubitemid 36799216)
17. Frederickson CJ, Koh JY, and Bush AI. The neurobiology of zinc in health and disease. Nat Rev Neurosci 6: 449-462, 2005. (Pubitemid 40774861)
18. Frederickson CJ, Maret W, and Cuajungco MP. Zinc and excitotoxic brain injury: a new model. Neuroscientist 10: 18-25, 2004. (Pubitemid 38112696)
19. Fu Y, Han J, Ishola T., Scerbo M, Adwanikar H, Ramsey C., and Neugebauer V. PKA and ERK, but not PKC, in the amygdala contribute to pain-related synaptic plasticity and behavior. Mol Pain 4: 26, 2008.
20. Garzón J., de la Torre-Madrid E, Rodríguez-Muñoz M, Vicente-Sánchez A, and Sánchez-Blázquez P. Gz mediates the long-lasting desensitization of brain CB1 receptors and is essential for cross-tolerance with morphine. Mol Pain 5: 11, 2009.
21. Garzón J., Rodríguez-Muñoz M, and Sánchez-Blazquez P. Direct association of Mu-opioid and NMDA glutamate receptors supports their cross-regulation: molecular implications for opioid tolerance. Curr Drug Abuse Rev 2012, 5: 199-226.
22. Garzón J., Rodríguez-Muñoz M, Vicente-Sánchez A, Bailón C, Martínez-Murillo R, and Sánchez- Blázquez P. RGSZ2 binds to the neural nitric oxide synthase PDZ domain to regulate mu-opioid receptor-mediated potentiation of the N-methyl-D-aspartate receptor-calmodulin-dependent protein kinase II pathway. Antioxid Redox Signal 15: 873-887, 2011.
23. Ghalandari-Shamami M., Hassanpour-Ezatti M, and Haghparast A. Intra-accumbal NMDA but not AMPA/kainate receptor antagonist attenuates WIN55,212-2 cannabinoid receptor agonist-induced antinociception in the basolateral amygdala in a rat model of acute pain. Pharmacol Biochem Behav 100: 213-219, 2011.
24. Guang W, Wang H, Su T., Weinstein IB, and Wang JB. Role of mPKCI, a novel mu-opioid receptor interactive protein, in receptor desensitization, phosphorylation, and morphine-induced analgesia. Mol Pharmacol 66: 1285-1292, 2004. (Pubitemid 39411068)
25. Hampson RE, Miller F, Palchik G., and Deadwyler SA. Cannabinoid receptor activation modifies NMDA receptor mediated release of intracellular calcium: implications for endocannabinoid control of hippocampal neural plasticity. Neuropharmacology 60: 944-952, 2011.
26. Harrison PJ and Weinberger DR. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry 10: 40-68, 2005. (Pubitemid 40139588)
27. Harvey BS, Ohlsson KS, Maag J.L., Musgrave IF, and Smid SD. Contrasting protective effects of cannabinoids against oxidative stress and amyloid-beta evoked neurotoxicity in vitro. Neurotoxicology 33: 138-146, 2012.
28. Hohmann AG, Briley EM, and Herkenham M. Pre- and postsynaptic distribution of cannabinoid and mu opioid receptors in rat spinal cord. Brain Res 822: 17-25, 1999. (Pubitemid 29222825)
29. Hsieh C, Brown S, Derleth C., and Mackie K. Internalization and recycling of the CB1 cannabinoid receptor. J Neurochem 73: 493-501, 1999. (Pubitemid 29339821)
30. Iwata H, Takasusuki T, Yamaguchi S., and Hori Y. NMDA receptor 2B subunit-mediated synaptic transmission in the superficial dorsal horn of peripheral nerve-injured neuropathic mice. Brain Res 1135: 92-101, 2007. (Pubitemid 46176831)
31. Khaspekov LG, Brenz Verca MS, Frumkina LE, Hermann H, Marsicano G, and Lutz B. Involvement of brain-derived neurotrophic factor in cannabinoid receptor-dependent protection against excitotoxicity. Eur J Neurosci 19: 1691-1698, 2004. (Pubitemid 38482557)
32. Kim SH, Won SJ, Mao X.O., Jin K., and Greenberg DA. Molecular mechanisms of cannabinoid protection from neuronal excitotoxicity. Mol Pharmacol 69: 691-696, 2006. (Pubitemid 43363843)
33. Knott AB and Bossy-Wetzel E. Nitric oxide in health and disease of the nervous system. Antioxid Redox Signal 11: 541-554, 2009.
34. Kofalvi A, Rodrigues RJ, Ledent C, Mackie K., Vizi ES, Cunha RA, and Sperlagh B. Involvement of cannabinoid receptors in the regulation of neurotransmitter release in the rodent striatum: a combined immunochemical and pharmacological analysis. J Neurosci 25: 2874-2884, 2005. (Pubitemid 40389245)
35. Kreutz S, Koch M, Ghadban C., Korf HW, and Dehghani F. Cannabinoids and neuronal damage: differential effects of THC, AEA and 2-AG on activated microglial cells and degenerating neurons in excitotoxically lesioned rat organotypic hippocampal slice cultures. Exp Neurol 203: 246-257, 2007. (Pubitemid 44821182)
36. Kudoh SN, Nagai R, Kiyosue K., and Taguchi T. PKC and CaMKII dependent synaptic potentiation in cultured cerebral neurons. Brain Res 915: 79-87, 2001. (Pubitemid 32907494)
37. Lee MC, Smith FL, Stevens D.L., and Welch SP. The role of several kinases in mice tolerant to delta 9-tetrahydrocan-nabinol. J Pharmacol Exp Ther 305: 593-599, 2003. (Pubitemid 36459175)
38. Li Q, Yan H, Wilson W.A., and Swartzwelder HS. Modulation of NMDA and AMPA-mediated synaptic transmission by CB1 receptors in frontal cortical pyramidal cells. Brain Res 1342: 127-137, 2010.
39. Lipton SA. Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat Rev Drug Discov 5: 160-170, 2006.
40. Liu Q, Bhat M, Bowen W.D., and Cheng J. Signaling pathways from cannabinoid receptor-1 activation to inhibition of N-methyl-D-aspartic acid mediated calcium influx and neurotoxicity in dorsal root ganglion neurons. J Pharmacol Exp Ther 331: 1062-1070, 2009.
41. Liu Q, Puche AC, and Wang JB. Distribution and expression of protein kinase C interactive protein (PKCI/HINT1) in mouse central nervous system (CNS). Neurochem Res 33: 1263-1276, 2008.
42. Liu XJ and Salter MW. Glutamate receptor phosphorylation and trafficking in pain plasticity in spinal cord dorsal horn. Eur J Neurosci 32: 278-289, 2010.
43. Maeng S and Zarate CA Jr. The role of glutamate in mood disorders: results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects. Curr Psychiatry Rep 9: 467-474, 2007. (Pubitemid 350284937)
44. Marchalant Y, Cerbai F, Brothers H.M., and Wenk GL. Canna-binoid receptor stimulation is anti-inflammatory and improves memory in old rats. Neurobiol Aging 29: 1894-1901, 2008.
45. Marsicano G, Goodenough S, Monory K., Hermann H, Eder M, Cannich A., Azad SC, Cascio MG, Gutierrez SO, van der Stelt M, Lopez-Rodriguez ML, Casanova E, Schutz G, Zieglgansberger W, Di M, V, Behl C, and Lutz B. CB1 can-nabinoid receptors and on-demand defense against ex-citotoxicity. Science 302: 84-88, 2003. (Pubitemid 37210691)
46. Marsicano G and Lafenetre P. Roles of the endocannabinoid system in learning and memory. Curr Top Behav Neurosci 1: 201-230, 2009.
47. Marsicano G and Lutz B. Neuromodulatory functions of the endocannabinoid system. J Endocrinol Invest 29: 27-46, 2006.
48. Marsicano G, Moosmann B, Hermann H., Lutz B, and Behl C. Neuroprotective properties of cannabinoids against oxidative stress: role of the cannabinoid receptor CB1. J Neurochem 80: 448-456, 2002. (Pubitemid 36383028)
49. Mechri A, Saoud M, Khiari G., d'Amato T, Dalery J, and Gaha L. Glutaminergic hypothesis of schizophrenia: clinical research studies with ketamine. Encephale 27: 53-59, 2001. (Pubitemid 32234479)
50. Melis M, Pistis M, Perra S., Muntoni AL, Pillolla G, and Gessa GL. Endocannabinoids mediate presynaptic inhibition of glutamatergic transmission in rat ventral tegmental area dopamine neurons through activation of CB1 receptors. J Neurosci 24: 53-62, 2004. (Pubitemid 38181669)
51. Mizoguchi H, Watanabe C, Yonezawa A., and Sakurada S. New therapy for neuropathic pain. Int Rev Neurobiol 85: 249-260, 2009.
52. Mody I and MacDonald JF. NMDA receptor-dependent ex-citotoxicity: the role of intracellular Ca2 + release. Trends Pharmacol Sci 16: 356-359, 1995.
53. Ong WY and Mackie K. A light and electron microscopic study of the CB1 cannabinoid receptor in the primate spinal cord. J Neurocytol 28: 39-45, 1999. (Pubitemid 30040768)
54. Palmer GC. Neuroprotection by NMDA receptor antagonists in a variety of neuropathologies. Curr Drug Targets 2: 241-271, 2001. (Pubitemid 32821469)
55. Perroy J, Raynaud F, Homburger V., Rousset MC, Telley L, Bockaert J, and Fagni L. Direct interaction enables cross-talk between ionotropic and group I metabotropic glutamate receptors. J Biol Chem 283: 6799-6805, 2008.
56. Richardson JD, Aanonsen L, and Hargreaves KM. Hy-poactivity of the spinal cannabinoid system results in NMDA-dependent hyperalgesia. J Neurosci 18: 451-457, 1998. (Pubitemid 28046802)
57. Rodriguez JJ, Mackie K, and Pickel VM. Ultrastructural localization of the CB1 cannabinoid receptor in mu-opioid receptor patches of the rat Caudate putamen nucleus. J Neurosci 21: 823-833, 2001. (Pubitemid 32163123)
58. Rodríguez-Muñoz M, Sánchez-Blázquez P, Vicente-Sánchez A, Bailón C, Martín-Aznar B, and Garzón J. The histidine triad nucleotide-binding protein 1 supports mu-opioid re-ceptor-glutamate NMDA receptor cross-regulation. Cell Mol Life Sci 68: 2933-2949, 2011.
59. Rodríguez-Muñoz M, Sánchez-Blázquez P, Vicente-Sánchez A, Berrocoso E, and Garzón J. The Mu-opioid receptor and the NMDA receptor associate in PAG neurons: implications in pain control. Neuropsychopharmacology 37: 338-349, 2012.
60. Salio C, Fischer J, Franzoni M.F., and Conrath M. Pre- and postsynaptic localizations of the CB1 cannabinoid receptor in the dorsal horn of the rat spinal cord. Neuroscience 110: 755-764, 2002. (Pubitemid 34270545)
61. Sánchez-Blázquez P, Rodríguez-Muñoz M, Bailón C, and Garzón J. GPCRs promote the release of zinc ions mediated by nNOS/NO and the Redox transducer RGSZ2 protein. Antioxid Redox Signal 17: 1163-1177, 2012.
62. Sánchez-Blázquez P, Rodríguez-Muñoz M, Montero C, de la Torre-Madrid E, and Garzón J. Calcium/calmodulin-dependent protein kinase II supports morphine antino-ciceptive tolerance by phosphorylation of glycosylated phosducin-like protein. Neuropharmacology 54: 319-330, 2008.
63. Sensi SL and Jeng JM. Rethinking the excitotoxic ionic milieu: the emerging role of Zn(2+) in ischemic neuronal injury. Curr Mol Med 4: 87-111, 2004. (Pubitemid 38428646)
64. Shyu YJ, Hiatt SM, Duren H.M., Ellis RE, Kerppola TK, and Hu CD. Visualization of protein interactions in living Cae-norhabditis elegans using bimolecular fluorescence complementation analysis. Nat Protoc 3: 588-596, 2008. (Pubitemid 351516754)
65. Thorat SN and Bhargava HN. Effects of NMDA receptor blockade and nitric oxide synthase inhibition on the acute and chronic actions of delta 9-tetrahydrocannabinol in mice. Brain Res 667: 77-82, 1994.
66. Tingley WG, Ehlers MD, Kameyama K, Doherty C., Ptak JB, Riley CT, and Huganir RL. Characterization of protein kinase A and protein kinase C phosphorylation of the N-methyl-D-aspartate receptor NR1 subunit using phosphorylation site-specific antibodies. J Biol Chem 272: 5157-5166, 1997. (Pubitemid 27090073)
67. Vawter MP, Crook JM, Hyde T.M., Kleinman JE, Weinberger DR, Becker KG, and Freed WJ. Microarray analysis of gene expression in the prefrontal cortex in schizophrenia: a preliminary study. Schizophr Res 58: 11-20, 2002. (Pubitemid 35287279)
68. Vawter MP, Shannon WC, Ferran E, Matsumoto M., Overman K, Hyde TM, Weinberger D.R., Bunney WE, and Kleinman JE. Gene expression of metabolic enzymes and a protease inhibitor in the prefrontal cortex are decreased in schizophrenia. Neurochem Res 29: 1245-1255, 2004. (Pubitemid 39028877)
69. Zhuang SY, Bridges D, Grigorenko E., McCloud S, Boon A, Hampson R.E., and Deadwyler SA. Cannabinoids produce neuroprotection by reducing intracellular calcium release from ryanodine-sensitive stores. Neuropharmacology 48: 1086-1096, 2005. (Pubitemid 40725981)
70. Zimon M, Baets J, Almeida-Souza L, De V.E., Nikodinovic J., Parman Y, Battaloglu E, Matur Z., Guergueltcheva V, Tournev I, Auer-Grumbach M, De R.P., Petersen BS, Muller T, Fransen E, Van DP, Loscher WN, Barisic N, Mitrovic Z, Previtali SC, Topaloglu H, Bernert G, Beleza-Meireles A, Todorovic S, Savic-Pavicevic D, Ishpekova B, Lechner S, Peeters K, Ooms T, Hahn AF, Zuchner S, Timmerman V, Van DP, Rasic VM, Janecke AR, De JP, and Jordanova A. Loss-of-function mutations in HINT1 cause axonal neuropathy with neuromyotonia. Nat Genet 44: 1080-1083, 2012.
71. Zukin RS and Bennett MV. Alternatively spliced isoforms of the NMDARI receptor subunit. Trends Neurosci 18: 306-313, 1995.